methocarbamol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1747 532-03-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methocarbamol
  • glycerylguaiacolate carbamate
  • guaiacol glyceryl ether carbamate
  • guaiphenesin carbamate
  • guaiamar carbamate
A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
  • Molecular weight: 241.24
  • Formula: C11H15NO5
  • CLOGP: 0.15
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 91.01
  • ALOGS: -1.76
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
3 g P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 16, 1957 FDA AUXILIUM PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 77.23 12.56 158 18485 131731 50454750
Necrosis ischaemic 64.68 12.56 20 18623 779 50585702
Pneumonia streptococcal 54.24 12.56 21 18622 1610 50584871
Beta haemolytic streptococcal infection 48.48 12.56 20 18623 1810 50584671
Acquired haemophilia 46.31 12.56 16 18627 887 50585594
Gallbladder polyp 41.78 12.56 14 18629 707 50585774
Multiple drug therapy 37.62 12.56 17 18626 1920 50584561
Maternal exposure during pregnancy 37.03 12.56 7 18636 159771 50426710
Treatment failure 36.61 12.56 4 18639 137633 50448848
Diabetes mellitus inadequate control 35.19 12.56 33 18610 13112 50573369
Muscle spasms 33.42 12.56 112 18531 125441 50461040
Systemic lupus erythematosus 32.93 12.56 6 18637 140616 50445865
Drug intolerance 32.91 12.56 20 18623 219084 50367397
Infusion related reaction 32.43 12.56 11 18632 169546 50416935
Migraine 29.43 12.56 77 18566 75203 50511278
Drug hypersensitivity 29.28 12.56 175 18468 250835 50335646
Spinal operation 27.70 12.56 21 18622 6239 50580242
Glossodynia 26.90 12.56 5 18638 115564 50470917
Anxiety 26.90 12.56 133 18510 177473 50409008
Amnesia 26.32 12.56 52 18591 42208 50544273
Depression 25.85 12.56 125 18518 165298 50421183
Exposure via skin contact 25.02 12.56 7 18636 191 50586290
Fall 24.73 12.56 209 18434 334723 50251758
Surgery 22.33 12.56 40 18603 30165 50556316
Intervertebral disc protrusion 21.90 12.56 32 18611 20361 50566120
Off label use 20.83 12.56 97 18546 474329 50112152
Exercise tolerance decreased 20.80 12.56 16 18627 4858 50581623
Blood pressure inadequately controlled 20.06 12.56 15 18628 4365 50582116
Withdrawal syndrome 19.47 12.56 28 18615 17562 50568919
Pre-existing condition improved 19.35 12.56 18 18625 7079 50579402
Road traffic accident 18.97 12.56 33 18610 24319 50562162
Neutropenia 18.94 12.56 16 18627 147949 50438532
Respiratory arrest 18.77 12.56 37 18606 29972 50556509
Back disorder 18.71 12.56 20 18623 9285 50577196
Joint swelling 18.66 12.56 39 18604 245247 50341234
Fibromyalgia 18.60 12.56 47 18596 44931 50541550
Lower respiratory tract infection 18.50 12.56 6 18637 95195 50491286
Back pain 18.21 12.56 141 18502 219889 50366592
Analgesic drug level increased 18.17 12.56 10 18633 1721 50584760
Multiple sclerosis relapse 17.87 12.56 45 18598 42919 50543562
Hypertension 17.84 12.56 136 18507 211067 50375414
Suspected suicide 17.40 12.56 15 18628 5342 50581139
Exposure during pregnancy 16.86 12.56 12 18631 121003 50465478
Wound 16.81 12.56 9 18634 105785 50480696
Cardiac failure 16.24 12.56 4 18639 76036 50510445
Alopecia 16.20 12.56 42 18601 245005 50341476
Febrile neutropenia 15.97 12.56 8 18635 97659 50488822
Thyroiditis chronic 15.90 12.56 3 18640 12 50586469
Loss of consciousness 15.67 12.56 78 18565 104275 50482206
Product dose omission issue 15.31 12.56 118 18525 183720 50402761
Therapy interrupted 15.29 12.56 27 18616 20125 50566356
Attention deficit hyperactivity disorder 15.03 12.56 10 18633 2419 50584062
Therapy cessation 14.99 12.56 31 18612 25980 50560501
Oesophagitis 14.37 12.56 21 18622 13362 50573119
Memory impairment 13.87 12.56 62 18581 79298 50507183
Somnolence 13.76 12.56 101 18542 154884 50431597
Synovial cyst 13.75 12.56 16 18627 8150 50578331
Neck pain 13.51 12.56 49 18594 57018 50529463
Cardio-respiratory arrest 13.38 12.56 47 18596 53845 50532636
Pharyngeal swelling 13.26 12.56 12 18631 4554 50581927
Malignant neoplasm of spinal cord 13.04 12.56 3 18640 36 50586445
Feeling abnormal 13.04 12.56 85 18558 125407 50461074
Psoriasis 12.89 12.56 55 18588 68945 50517536
Illness 12.70 12.56 28 18615 24512 50561969
Suicidal ideation 12.64 12.56 47 18596 55338 50531143

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug dependence 85.31 14.87 59 7894 20922 29545652
Product prescribing error 55.90 14.87 43 7910 17933 29548641
Respiratory depression 52.54 14.87 37 7916 13486 29553088
Victim of child abuse 39.85 14.87 13 7940 832 29565742
Child abuse 35.85 14.87 9 7944 222 29566352
Depression 30.15 14.87 69 7884 85078 29481496
Phonophobia 28.03 14.87 7 7946 169 29566405
Back disorder 22.40 14.87 16 7937 5957 29560617
Epidural lipomatosis 22.07 14.87 8 7945 703 29565871
Memory impairment 20.67 14.87 36 7917 36434 29530140
Intentional product misuse 19.36 14.87 34 7919 34627 29531947
Anxiety 18.79 14.87 58 7895 85307 29481267
Serum procollagen type III N-terminal propeptide increased 18.14 14.87 4 7949 55 29566519
Spinal operation 18.00 14.87 10 7943 2404 29564170
Back pain 17.64 14.87 64 7889 102220 29464354
Juvenile idiopathic arthritis 16.86 14.87 8 7945 1386 29565188
Post-traumatic neck syndrome 15.77 14.87 4 7949 103 29566471

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 65.68 12.42 189 20514 224225 64253804
Necrosis ischaemic 63.31 12.42 20 20683 963 64477066
Drug dependence 57.73 12.42 62 20641 33250 64444779
Beta haemolytic streptococcal infection 50.49 12.42 20 20683 1874 64476155
Pneumonia streptococcal 46.09 12.42 20 20683 2358 64475671
Gallbladder polyp 40.44 12.42 14 20689 898 64477131
Acquired haemophilia 39.35 12.42 16 20687 1604 64476425
Victim of child abuse 37.20 12.42 13 20690 858 64477171
Anxiety 36.44 12.42 145 20558 202504 64275525
Product prescribing error 35.63 12.42 50 20653 35219 64442810
Depression 35.27 12.42 134 20569 183157 64294872
Child abuse 34.70 12.42 9 20694 211 64477818
Respiratory depression 31.08 12.42 38 20665 23405 64454624
Back disorder 29.56 12.42 25 20678 9965 64468064
Respiratory arrest 28.98 12.42 57 20646 52928 64425101
Spinal operation 28.35 12.42 20 20683 6113 64471916
Multiple drug therapy 28.21 12.42 14 20689 2240 64475789
Neutropenia 27.45 12.42 22 20681 239602 64238427
Exposure via skin contact 27.12 12.42 7 20696 161 64477868
Migraine 26.82 12.42 61 20642 62616 64415413
Drug hypersensitivity 25.79 12.42 147 20556 237668 64240361
Fall 24.91 12.42 223 20480 416603 64061426
Drug intolerance 24.51 12.42 15 20688 187977 64290052
Contraindicated product administered 24.30 12.42 3 20700 107826 64370203
Back pain 24.15 12.42 150 20553 250021 64228008
Infusion related reaction 23.05 12.42 12 20691 164455 64313574
Muscle spasms 23.03 12.42 98 20605 140925 64337104
Memory impairment 22.94 12.42 70 20633 85612 64392417
Cardiac failure 22.90 12.42 7 20696 132366 64345663
Diabetes mellitus inadequate control 22.69 12.42 31 20672 21290 64456739
Drug abuser 22.45 12.42 17 20686 5791 64472238
Pancytopenia 22.35 12.42 9 20694 143300 64334729
Back injury 22.11 12.42 19 20684 7738 64470291
Thrombocytopenia 21.58 12.42 24 20679 223777 64254252
Intentional product misuse 21.20 12.42 61 20642 72234 64405795
Road traffic accident 20.48 12.42 36 20667 30709 64447320
Surgery 20.05 12.42 34 20669 28179 64449850
Contusion 20.02 12.42 81 20622 113884 64364145
Phonophobia 19.87 12.42 7 20696 473 64477556
Multiple sclerosis relapse 19.83 12.42 42 20661 41093 64436936
Epidural lipomatosis 19.06 12.42 8 20695 869 64477160
Intervertebral disc degeneration 18.59 12.42 22 20681 13098 64464931
Feeling abnormal 18.19 12.42 88 20615 133514 64344515
Overdose 18.18 12.42 100 20603 159466 64318563
Pain 18.00 12.42 263 20440 553248 63924781
Serum procollagen type III N-terminal propeptide increased 17.93 12.42 4 20699 48 64477981
Loss of consciousness 17.59 12.42 94 20609 148271 64329758
Amnesia 17.44 12.42 44 20659 48225 64429804
Treatment failure 17.16 12.42 8 20695 116808 64361221
Analgesic drug level increased 16.92 12.42 10 20693 2260 64475769
Hypertension 16.65 12.42 141 20562 259120 64218909
Intervertebral disc protrusion 16.61 12.42 26 20677 20165 64457864
Off label use 16.15 12.42 128 20575 632678 63845351
Suicidal ideation 15.65 12.42 52 20651 66490 64411539
Emotional distress 15.33 12.42 35 20668 36003 64442026
Attention deficit hyperactivity disorder 15.09 12.42 10 20693 2760 64475269
Pain in extremity 15.03 12.42 156 20547 302929 64175100
Cardio-respiratory arrest 15.00 12.42 67 20636 98326 64379703
Maternal exposure during pregnancy 14.98 12.42 6 20697 95878 64382151
Blood pressure inadequately controlled 14.96 12.42 13 20690 5371 64472658
Malignant neoplasm progression 14.71 12.42 9 20694 112862 64365167
Insomnia 14.55 12.42 111 20592 197725 64280304
Oesophageal stenosis 14.33 12.42 11 20692 3823 64474206
Therapy cessation 14.32 12.42 32 20671 32457 64445572
Interstitial lung disease 13.89 12.42 7 20696 97725 64380304
Pyrexia 13.78 12.42 114 20589 558530 63919499
Systemic lupus erythematosus 13.61 12.42 4 20699 77608 64400421
Suspected suicide 13.08 12.42 15 20688 8639 64469390
Intervertebral disc displacement 13.04 12.42 5 20698 429 64477600
Drug interaction 12.94 12.42 66 20637 362017 64116012
Therapy interrupted 12.75 12.42 23 20680 20013 64458016
Pharyngeal swelling 12.66 12.42 12 20691 5547 64472482
Vision blurred 12.66 12.42 60 20643 90256 64387773
Spinal osteoarthritis 12.54 12.42 19 20684 14322 64463707
Febrile neutropenia 12.42 12.42 26 20677 187631 64290398

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03BA03 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Carbamic acid esters
ATC M03BA53 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Carbamic acid esters
ATC M03BA73 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Carbamic acid esters
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:51371 muscle relaxants
FDA PE N0000175730 Centrally-mediated Muscle Relaxation
FDA EPC N0000175737 Muscle Relaxant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Spasticity indication 221360009
Muscle Spasm with Pain indication
Tetanus Adjunct Treatment indication
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Gastrointestinal ulcer contraindication 40845000
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Acute nephropathy contraindication 58574008
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Anemia due to enzyme deficiency contraindication 111577008
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001
Acute erosive gastritis contraindication 444926003




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Acute inflammatory and traumatic conditions of the skeletal muscles Indication
Cats Reducing muscular spasms Indication
Dogs Acute inflammatory and traumatic conditions of the skeletal muscles Indication
Dogs Reducing muscular spasms Indication
Horses Acute inflammatory and traumatic conditions of the skeletal muscles Indication
Horses Reducing muscular spasms Indication

🐶 Veterinary products

ProductApplicantIngredients
Robaxin-V Injectable Kinetic Technologies LLC 1
Robaxin-V Tablets Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 1 Enzyme INHIBITOR Ki 7.60 IUPHAR CHEMBL

External reference:

IDSource
4017879 VUID
N0000146232 NUI
D00402 KEGG_DRUG
4017879 VANDF
C0025659 UMLSCUI
CHEBI:6832 CHEBI
CHEMBL1201117 ChEMBL_ID
DB00423 DRUGBANK_ID
D008721 MESH_DESCRIPTOR_UI
4107 PUBCHEM_CID
6829 IUPHAR_LIGAND_ID
776 INN_ID
125OD7737X UNII
6845 RXNORM
5075 MMSL
988 MMSL
d00965 MMSL
001669 NDDF
387486000 SNOMEDCT_US
83973001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0143-1290 TABLET 500 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0143-1292 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0404-9909 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 11 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0404-9909 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 11 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0440-1740 TABLET 500 mg ORAL ANDA 23 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0517-1825 INJECTION 100 mg INTRAMUSCULAR ANDA 20 sections
ROBAXIN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6103 INJECTION 100 mg INTRAMUSCULAR NDA 22 sections
ROBAXIN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6217 INJECTION 100 mg INTRAMUSCULAR NDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7057 TABLET 500 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7057 TABLET 500 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7058 TABLET 750 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7058 TABLET 750 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10135-664 TABLET, FILM COATED 500 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10135-665 TABLET, FILM COATED 750 mg ORAL ANDA 19 sections
Methocarbamol Tablets, USP, 500 mg HUMAN PRESCRIPTION DRUG LABEL 1 10135-722 TABLET, FILM COATED 500 mg ORAL ANDA 20 sections
Methocarbamol Tablets, USP, 750 mg HUMAN PRESCRIPTION DRUG LABEL 1 10135-723 TABLET, FILM COATED 750 mg ORAL ANDA 20 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-259 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-464 TABLET 750 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-622 TABLET 750 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-773 TABLET 500 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-956 TABLET 750 mg ORAL ANDA 23 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 16590-147 TABLET 500 mg ORAL ANDA 21 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 16590-148 TABLET 750 mg ORAL ANDA 21 sections
ROBAXIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-981 TABLET, FILM COATED 750 mg ORAL NDA 11 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 17511-505 TABLET, FILM COATED 500 mg ORAL ANDA 20 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 17511-506 TABLET, FILM COATED 750 mg ORAL ANDA 20 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 21695-078 TABLET 500 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 21695-079 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 25021-675 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 23 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 31722-533 TABLET 500 mg ORAL ANDA 19 sections